Emtora Biosciences Presents Phase Ib Data in Low Grade Prostate Cancer Patients at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
10 February 2020 - - US-based clinical stage life science company Emtora Biosciences made a poster presentation at the American Society of Clinical Oncology and Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium, the company said.

Emtora's core technology incorporates submicron rapamycin particles into a pH-sensitive polymer, improving bioavailability and allowing for consistent and lower dosing than generic rapamycin.

Emtora was awarded a grant from the Cancer Prevention and Research Institute of Texas (CPRIT) in 2019 to continue the advancement of eRapa in a Phase 2a trial, which is scheduled to begin in April 2020.

The poster features results of the company's Phase 1b trial of eRapa in 14 low grade prostate cancer patients.

eRapa capitalises on the potential of partial and/or intermittent inhibition of the mechanistic target of rapamycin to act as a cancer immuno-oncology and chemopreventative agent.

In patients with low-grade PCa, treatment with low dose eRapa was found to be safe and well-tolerated.

The dose of 0.5mg daily produced predictable, low, and stable blood concentration levels through the duration of treatment and resulted in a positive immune impact by enhancing CD8+ memory T cells.

Emtora Biosciences is a clinical stage biopharmaceutical company headquartered in San Antonio, Texas.

The company holds the exclusive license to eRapa, an improved formulation of rapamycin originally developed at UT Health San Antonio that is being investigated to prevent cancer and other age-related medical conditions.

Emtora is strategically developing and commercialising eRapa for indications where there are serious unmet medical needs.


Related Headlines